Oxidized low density lipoprotein and innate immune receptors

Current Opinion in Lipidology

Volumn 14, Issue 5, 2003, Pages 437-445

  Miller, Yury I ^a,b   Chang, Mi Kyung ^a   Binder, Christoph J ^a   Shaw, Peter X ^a   Witztum, Joseph L ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

C reactive protein; CD14; Oxidized LDL; Scavenger receptors; Toll like receptors

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; COMPLEMENT; CYTOKINE; FC RECEPTOR; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; RECEPTOR; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4;

ATHEROGENESIS; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CELL ACTIVITY; CYTOKINE RELEASE; CYTOSKELETON; ENDOCYTOSIS; EPIDEMIOLOGICAL DATA; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; IMMUNE SYSTEM; IMMUNITY; INFLAMMATION; LIPID OXIDATION; MACROPHAGE; MOLECULAR RECOGNITION; NONHUMAN; PATHOGENESIS; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LIPID INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STIMULATION;

ANIMALS; ANTIGENS, CD14; ARTERIOSCLEROSIS; C-REACTIVE PROTEIN; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOKINE; RECEPTORS, IMMUNOLOGIC; RECEPTORS, SCAVENGER; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS;

EID: 0142029569     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200310000-00004     Document Type: Review

References (72)

1. Hörkkö S, Binder CJ, Shaw PX, et al. Immunological responses to oxidized LDL. Free Radic Biol Med 2000; 28:1771-1779.
2. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:1876-1890.
3. Hansson GK, Libby P, Schonbeck U, Van ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91:281-291.
4. Binder CJ, Chang MK, Shaw PX, et al. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8:1218-1226. These reviews provide a comprehensive overview of the role of immune mechanisms in atherogenesis. In addition to the evidence that these may impact lesion formation, the authors suggest novel therapeutic approaches to modulate atherogenesis.
5. Ochsenbein AF, Fehr T, Lutz C, et al. Control of early viral and bacterial distribution and disease by natural antibodies. Science 1999; 286:2156-2159.
6. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105:1135-1143. This review describes the basic inflammatory mechanisms of atherogenesis as well as clinical markers of inflammation and their correlation with an adverse prognosis of cardiovascular disease.
7. Medzhitov R, Preston-Hurlburt P, Janeway Jr CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-397.
8. Akira S. Mammalian Toll-like receptors. Curr Opin Immunol 2003; 15:5-11. This is a concise comprehensive review of TLRs, reporting on the current developments and future directions of TLR research.
9. Wang PY, Kitchens RL, Munford RS. Phosphatidylinositides bind to plasma membrane CD14 and can prevent monocyte activation by bacterial lipopolysaccharide. J Biol Chem 1998; 273:24309-24313.
10. Akashi S, Ogata H, Kirikae F, et al. Regulatory roles for CD14 and phosphatidylinositol in the signaling via toll-like receptor 4-MD-2. Biochem Biophys Res Commun 2000; 268:172-177.
11. Yu B, Hailman E, Wright SD. Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. J Clin Invest 1997; 99:315-324.
12. Sugiyama T, Wright SD. Soluble CD14 mediates efflux of phospholipids from cells. J Immunol 2001; 166:826-831.
13. Miller Y, Viriyakosol S, Binder CJ, et al. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003; 278:1561-1568. This paper shows that mmLDL affects the cytoskeletal organization of macrophages mediated by CD14 and TLR4. The mmLDL-induced spreading of macrophages inhibits their ability to phagocytose apoptotic cells but enhances the uptake of oxidized LDL.
14. Bochkov VN, Kadl A, Huber J, et al. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature 2002; 419:77-81. Oxidized PC-containing lipids are known for their pro-inflammatory effects. This paper, however, suggests that these oxidized lipids protect from adverse lipopolysaccharide-induced effects, both in vitro and in vivo. The authors explain these findings by the competition between oxidized lipids and lipopolysaccharide for CD14 binding.
15. Walton KA, Hsieh X, Gharavi N, et al. Receptors involved in the Ox-PAPC-mediated synthesis of IL-8: a role for toll-like receptor 4 and a GPI anchored protein. J Biol Chem 2003; May 30 [Epub ahead of print]. This paper shows that oxidized PAPC stimulates IL-8 synthesis in endothelial cells, and that this is mediated by TLR4 and a GPI anchored receptor distinct from CD14.
16. Berliner JA, Subbanagounder G, Leitinger N, et al. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med 2001; 11:142-147.
17. Walton KA, Cole AL, Yen M, et al. Specific phospholipid oxidation products inhibit ligand activation of Toll-like receptors 4 and 2. Arterioscler Thromb Vasc Biol 2003; 23:1197-1203. This paper reports that OxPAPC inhibits LPS-induced TLR4-dependent secretion of IL-8 and MCP-1 in endothelial cells. It also describes a novel mechanism that involves alterations to lipid raft/caveolar processing, by which specific phospholipid oxidation products inhibit activation by TLR4 and TLR2 ligands.
18. Liao F, Andalibi A, deBeer FC, et al. Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice. J Clin Invest 1993; 91:2572-2579.
19. Shi W, Haberland ME, Jien ML, et al. Endothelial responses to oxidized lipoproteins determine genetic susceptibility to atherosclerosis in mice. Circulation 2000; 102:75-81.
20. Vink A, Schoneveld AH, van der Meer JJ, et al. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 2002; 106:1985-1990.
21. Lehr HA, Sagban TA, Ihling C, et al. Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation 2001; 104:914-920.
22. Wright SD, Burton C, Hernandez M, et al. Infectious agents are not necessary for murine atherogenesis. J Exp Med 2000; 191:1437-1442.
23. Dansky HM, Charlton SA, Harper MM, Smith JD. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 1997; 94:4642-4646.
24. Reardon CA, Blachowicz L, White T, et al. Effect of immune deficiency on lipoproteins and atherosclerosis in male apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21:1011-1016.
25. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347:185-192. This paper strongly supports the importance of the TLR4 in human atherosclerosis by showing that a polymorphism that attenuates receptor signaling was associated with a decreased risk of atherosclerosis.
26. Xu XH, Shah PK, Faure E, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104:3103-3108.
27. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105:1158-1161.
28. Hubacek JA, Rothe G, Pit'ha J, et al. C(-260)→T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999; 99:3218-3220.
29. Nauck M, Winkelmann BR, Hoffmann MM, et al. C(-260)T polymorphism in the promoter of the CD14 gene is not associated with coronary artery disease and myocardial infarction in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Am J Cardiol 2002; 90:1249-1252. This paper and Refs 28 and 30 demonstrate that there is no consensus on whether the C(-260)T CD14 promoter polymorphism is a risk factor for cardiovascular disease.
30. Zee RY, Lindpaintner K, Struk B, et al. A prospective evaluation of the CD14 C(-260)T gene polymorphism and the risk of myocardial infarction. Atherosclerosis 2001; 154:699-702.
31. Risley P, Jerrard-Dunne P, Sitzer M, et al. Promoter polymorphism in the endotoxin receptor (CD14) is associated with increased carotid atherosclerosis only in smokers: the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2003; 34:600-604. This paper demonstrates a prognostic value of the C(-159)T CD14 promoter polymorphism for carotid atherosclerosis in smokers.
32. Patino R, Ibarra J, Rodriguez A, et al. Circulating monocytes in patients with diabetes mellitus, arterial disease, and increased CD14 expression. Am J Cardiol 2000; 85:1288-1291.
33. Kabarowski JH, Zhu K, Le LQ, et al. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 2001; 293:702-705.
34. Xu Y. Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction. Biochim Biophys Acta 2002; 1582:81-88. This review details ligand specificity and signaling cascades of G2A and other recently identified receptors for lysophosphatidylcholine and Sphingosylphosphorylcholine.
35. Rikitake Y, Hirata K, Yamashita T, et al. Expression of G2A, a receptor for lysophosphatidylcholine, by macrophages in murine, rabbit, and human atherosclerotic plaques. Arterioscler. Thromb Vasc Biol 2002; 22:2049-2053. This paper demonstrates that macrophages abundantly express G2A, and suggests that G2A may play a role in the formation of atherosclerotic lesions.
36. Friedman P, Hörkkö S, Steinberg D, et al. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids: Importance of Schiff base formation and Aldol condensation. J Biol Chem 2002; 277:7010-7020. The paper details the chemical basis of the recognition of oxidized PC-containing lipids by the natural, innate antibody, EO6.
37. Chang MK, Bergmark C, Laurila A, et al. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci U S A 1999; 96:6353-6358.
38. Hörkkö S, Bird DA, Miller E, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 1999; 103:117-128.
39. Shaw PX, Hörkkö S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000; 105:1731-1740.
40. Binder CJ, Hörkkö S, Dewan A, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumonias and oxidized LDL. Nat Med 2003; 9:736-743. This paper proves that the molecular mimicry between OxLDL and bacterial pathogens previously demonstrated in vitro occurs in vivo and plays an important role in atherogenesis. If the findings are applicable in humans, they suggest new therapeutic strategies to fight cardiovascular disease.
41. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 2002; 99:13043-13048. This paper suggests that in addition to the clinical significance of CRP levels as a risk factor for cardiovascular disease, CRP may play a role in the pathogenesis of atherosclerosis as a result of its binding to OxLDL and apoptotic cells.
42. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol Immunol 2001; 38:189-197.
43. Szalal AJ. The antimicrobial activity of C-reactive protein. Microbes Infect 2002; 4:201-205. This paper provides a comprehensive review of CRP biology and its traditional antimicrobial role.
44. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107:363-369. This review gives a current overview of the clinical significance of CRP levels, compares CRP with other risk factors for cardiovascular disease, and sets goals of screening, therapeutic options and clinical recommendations.
45. Fu T, Borensztajn J. Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem J 2002; 366:195-201.
46. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998; 18:1386-1392.
47. Viriyakosol S, Tobias PS, Kitchens RL, Kirkland TN. MD-2 binds to bacterial lipopolysaccharide. J Biol Chem 2001; 276:38044-38051.
48. Inohara N, Nuñez G. ML: a conserved domain involved in innate immunity and lipid metabolism. Trends Biochem Sci 2002; 27:219-221. This paper introduces a new family of MD-2-related lipid-recognition proteins, which carry a common MD-2-related lipid-recognition domain, and mediate diverse biological functions through interacting with specific lipids.
49. Krieger M. The other side of scavenger receptors: pattern recognition for host defense. Curr Opin Lipidol 1997; 8:275-280.
50. Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002; 2:965-975. This is a comprehensive review of the immunological consequences of the phagocytosis of apoptotic cells.
51. Suzuki H, Kurihara Y, Takeya M, et al. The multiple roles of macrophage scavenger receptors (MSR) in vivo: resistance to atherosclerosis and susceptibility to infection in MSR knockout mice. J Atheroscler Thromb 1997; 4:1-11.
52. Peiser L, De Winther MP, Makepeace K, et al. The class A macrophage scavenger receptor is a major pattern recognition receptor for Neisseria meningitidis which is independent of lipopolysaccharide and not required for secretory responses. Infect Immun 2002; 70:5346-5354.
53. Smith TG, Serghides L, Patel SN, et al. CD36-mediated nonopsonic phagocytosis of erythrocytes infected with stage I and IIA gametocytes of Plasmodium falciparum. Infect Immun 2003; 71:393-400.
54. Vishnyakova TG, Bocharov AV, Baranova IN, et al. Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1. J Biol Chem 2003; 278:22771-22780. This paper describes a new role for Cla-1 as a lipopolysaccharide-binding protein and details the Cla-1-mediated lipopolysaccharide internalization and intracellular sorting.
55. Kunjathoor W, Febbraio M, Podrez EA, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002; 277:49982-49988.
56. Boullier A, Gillotte KL, Hörkkö S, et al. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J Biol Chem 2000; 275:9163-9169.
57. Boullier A, Bird DA, Chang MK, et al. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann NY Acad Sci 2001; 947:214-222.
58. Gillotte-Taylor K, Boullier A, Witztum JL, et al. Scavenger receptor class B type I as a receptor for oxidized low density lipoprotein. J Lipid Res 2001; 42:1474-1482.
59. Podrez EA, Poliakov E, Shen Z, et al. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem 2002; 277:38517-38523.
60. Podrez EA, Poliakov E, Shen Z, et al. Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem 2002; 277:38503-38516.
61. Huber J, Vales A, Mitulovic G, et al. Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol 2002; 22:101-107.
62. Moore KJ, El Khoury J, Medeiros LA, et al. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J Biol Chem 2002: 277:47373-47379. This paper shows that CD36 is not only a scavenger receptor but also initiates a signaling cascade mediated by beta-amyloid binding. It is not yet known whether OxLDL binding to CD36 also initiates such signaling.
63. Bertin J, Nir WJ, Fischer CM, et al. Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-kappaB. J Biol Chem 1999; 274:12955-12958.
64. Inohara N, Koseki T, del Peso L, et al. Nod1, an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J Biol Chem 1999; 274:14560-14567.
65. Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276:4812-4818.
66. Inohara N, Ogura Y, Nuñez G. Nods: a family of cytosolic proteins that regulate the host response to pathogens. Curr Opin Microbiol 2002; 5:76-80. This is an excellent short introduction to the NOD family of intracellular proteins, which are involved in the recognition of pathogen components in the cytosol of mammalian cells.
67. Girardin SE, Sansonetti PJ, Philpott DJ. Intracellular vs extracellular recognition of pathogens: common concepts in mammals and flies. Trends Microbiol 2002; 10:193-199. This review compares pathogen recognition by extracellular TLRs and intracellular NOD receptors in mammals and tracks phylogenetic parallels between mammals, insects and plants.
68. Inohara N, Nuñez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003; 3:371-382. This is a comprehensive review summarizing current developments in the area of intracellular pathogen receptors and discussing the role of NODs in regulating inflammatory responses and apoptosis.
69. Stevens DL. Toll receptors, CD14, MD-2 and NOD2: their role in health and acute and chronic infectious diseases. Curr Opin Infect Dis 2002; 15:219-220.
70. Huang JT, Welch JS, Ricote M, et al. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999; 400:378-382.
71. Davies SS, Pontsler AV, Marathe GK, et al. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. J Biol Chem 2001; 276:16015-16023.
72. Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000; 106:523-531.